National Cancer Institute; Notice of Closed Meetings, 66463-66464 [2023-20956]
Download as PDF
<![CDATA[
ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Clinical Integrative Cardiovascular
and Hematological Sciences Study Section.
Date: October 19–20, 2023.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Alexandria Old
Town, 1900 Diagonal Road, Alexandria, VA
22314.
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4126,
MSC 7814, Bethesda, MD 20892, (301) 435–
1743, margaret.chandler@nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group; Biodata Management and Analysis
Study Section.
Date: October 19–20, 2023.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Bethesdan Hotel, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: E. Bryan Crenshaw, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 480–7129, bryan.crenshaw@
nih.gov.
Name of Committee: Surgical Sciences,
Biomedical Imaging and Bioengineering
Integrated Review Group; Clinical
Translational Imaging Science Study Section.
Date: October 19–20, 2023.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: North Bethesda Marriott Hotel &
Conference Center, Montgomery County
Conference Center Facility, 5701 Marinelli
Road North, Bethesda, MD 20852.
Contact Person: Eleni Apostolos Liapi, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, (301) 867–5309, eleni.liapi@nih.gov.
Name of Committee: Healthcare Delivery
and Methodologies Integrated Review Group;
Interdisciplinary Clinical Care in Specialty
Care Settings Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Bethesdan Hotel, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Abu Saleh Mohammad
Abdullah, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 827–4043,
abuabdullah.abdullah@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
VerDate Sep<11>2014
18:44 Sep 26, 2023
Jkt 259001
Dated: September 21, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–20980 Filed 9–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Development and
Commercialization of Engineered T
Cell Therapies for the Treatment of
Cancer
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the SUPPLEMENTARY INFORMATION
section of this notice to Moonlight Bio,
Inc. (‘‘Moonlight’’), headquartered in
Seattle, WA.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before October 12, 2023 will be
considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries, and
comments relating to the contemplated
Exclusive Patent License should be
directed to: Andrew Burke, Ph.D.,
Senior Technology Transfer Manager,
NCI Technology Transfer Center,
Telephone: (240)-276–5484; Email:
andy.burke@nih.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Intellectual Property
1. United States Provisional Patent
Application No. 63/492,256 filed March
27, 2023, entitled ‘‘T Cell Receptors
Targeting Y220C or R175H Mutation in
P53’’ [HHS Reference No. E–054–2023–
0–US–01].
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to the
following:
‘‘Development, manufacture and
commercialization of autologous T cell
therapy products genetically engineered
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
66463
to express a P53 R175H-reactive TCR
claimed in the Licensed Patent Rights
for the treatment of cancer in humans.’’
The E–054–2023 patent family is
primarily directed to isolated T cell
receptors (TCRs) reactive to certain
mutated forms of tumor protein 53
(TP53 or P53), within the context of
several human leukocyte antigens. P53
is the archetypal tumor suppressor gene
and the most frequently mutated gene in
cancer. Contemporary estimates suggest
that >50% of all tumors carry mutations
in P53. Because of its prevalence in
cancer and its restricted expression to
precancerous and cancerous cells, this
antigen may be targeted on mutant P53expressing tumors with minimal normal
tissue toxicity.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 21, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2023–21050 Filed 9–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
E:\FR\FM\27SEN1.SGM
27SEN1
66464
Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES1
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; R13
Conference Grant Review.
Date: November 14–15, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W542, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Biman Chandra Paria,
Ph.D., Scientific Review Officer, Program
Coordination and Referral Branch, Division
of Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W542, Rockville, Maryland 20850,
240–858–3814, pariab@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SBIR Phase
IIB Bridge Awards.
Date: November 16, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W238, Rockville, Maryland
20850, 240–276–6371, decluej@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Small
Business Transition Grant for Early Career
Scientists.
Date: November 30, 2023.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W238, Rockville, Maryland 20850
(Telephone Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D.,
Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W238, Rockville, Maryland
20850, 240–276–6371, decluej@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
VerDate Sep<11>2014
18:44 Sep 26, 2023
Jkt 259001
Cancer Control, National Institutes of Health,
HHS)
Dated: September 21, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–20956 Filed 9–26–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Oncology 2—
Translational Clinical Integrated Review
Group; Translational Immuno-oncology
Study Section.
Date: October 19–20, 2023.
Time: 8:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, Bethesda, MD
20814.
Contact Person: Maria Elena
Cardenas-Corona, Ph.D.. Scientific
Review Officer, Center for Scientific
Review, National Institutes of Health,
6701 Rockledge Drive, Bethesda, MD
20817, 301–867–5309, maria.cardenascorona@nih.gov.
Name of Committee: Infectious
Diseases and Immunology B Integrated
Review Group; Transplantation,
Tolerance, and Tumor Immunology
Study Section.
Date: October 19–20, 2023.
Time: 8:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Canopy by Hilton, 940 Rose
Avenue, North Bethesda, MD 20852.
Contact Person: Carmen Angeles
Ufret-Vincenty, Ph.D., Scientific Review
Officer, Center for Scientific Review,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
(301) 594–0912, carmen.ufret-vincenty@
nih.gov.
Name of Committee: Molecular,
Cellular and Developmental
Neuroscience Integrated Review Group;
Molecular and Cellular
Neuropharmacology Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vanessa S Boyce,
Ph.D., Scientific Review Officer, Center
for Scientific Review, National Institutes
of Health, 6701 Rockledge Drive, Rm.
4185, MSC 7850, Bethesda, MD 20892,
(301) 402–3726, boycevs@csr.nih.gov.
Name of Committee: Center for
Scientific Review Special Emphasis
Panel; Collaborative Applications:
Clinical Studies of Mental Illness.
Date: October 19, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Allison Kurti, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room
1007J, Bethesda, MD 20892, (301) 594–
1814, kurtian@csr.nih.gov.
Name of Committee: Population
Sciences and Epidemiology Integrated
Review Group; Neurological, Mental
and Behavioral Health Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Allison Kurti, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room
1007J, Bethesda, MD 20892, (301) 594–
1814, kurtian@csr.nih.gov.
Name of Committee: Vascular and
Hematology Integrated Review Group;
Hemostasis, Thrombosis, Blood Cells
and Transfusion Study Section.
Date: October 19–20, 2023.
Time: 9:00 a.m. to 9:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vivian Tang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
E:\FR\FM\27SEN1.SGM
27SEN1
]]>Agencies
[Federal Register Volume 88, Number 186 (Wednesday, September 27, 2023)]
[Notices]
[Pages 66463-66464]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-20956]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
[[Page 66464]]
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; R13 Conference Grant Review.
Date: November 14-15, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W542, Rockville, Maryland 20850 (Virtual
Meeting).
Contact Person: Biman Chandra Paria, Ph.D., Scientific Review
Officer, Program Coordination and Referral Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W542, Rockville, Maryland 20850, 240-858-3814,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; SBIR Phase IIB Bridge Awards.
Date: November 16, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W238, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W238, Rockville, Maryland 20850, 240-276-6371,
[email protected].
Name of Committee: National Cancer Institute Special Emphasis
Panel; Small Business Transition Grant for Early Career Scientists.
Date: November 30, 2023.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Cancer Institute at Shady Grove, 9609 Medical
Center Drive, Room 7W238, Rockville, Maryland 20850 (Telephone
Conference Call).
Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review
Officer, Research Technology and Contract Review Branch, Division of
Extramural Activities, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W238, Rockville, Maryland 20850, 240-276-6371,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: September 21, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-20956 Filed 9-26-23; 8:45 am]
BILLING CODE 4140-01-P
